Amedeo Smart

Free Medical Literature Service



HIV Infection

  Free Subscription


1 Am J Epidemiol
1 Antimicrob Agents Chemother
4 Antivir Ther
40 Clin Infect Dis
14 J Acquir Immune Defic Syndr
2 J Immunol
1 J Med Virol
4 J Virol
1 Lancet Gastroenterol Hepatol
4 Lancet HIV
1 MMWR Morb Mortal Wkly Rep
1 Nat Rev Immunol
1 Neurology
3 Pediatr Infect Dis J
13 PLoS One
1 PLoS Pathog
1 Vaccine
1 Virology


  1. MENZA TW, Billock R, Samoff E, Eron JJ, et al
    Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.
    AIDS. 2017;31:2235-2244.
    >> Share

  2. HOORNENBORG E, Krakower DS, Prins M, Mayer KH, et al
    Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries.
    AIDS. 2017;31:2179-2191.
    >> Share

  3. MIKKELSEN E, Hontelez JAC, Nonvignon J, Amon S, et al
    The costs of HIV treatment and care in Ghana.
    AIDS. 2017;31:2279-2286.
    >> Share

  4. TASSIOPOULOS K, Abdo M, Wu K, Koletar SL, et al
    Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults.
    AIDS. 2017;31:2287-2294.
    >> Share

  5. SIEGENBEEK VAN HEUKELOM ML, Marra E, de Vries HJC, van der Loeff MFS, et al
    Risk factors for anal high-grade squamous intraepithelial lesions in HIV-positive MSM: is targeted screening possible?
    AIDS. 2017;31:2295-2301.
    >> Share

  6. VASE MO, Ludvigsen M, Bendix K, Dutoit SH, et al
    Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma.
    AIDS. 2017;31:2311-2313.
    >> Share

  7. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    >> Share

    Am J Epidemiol

  8. HOWE CJ, Dulin-Keita A, Cole SR, Hogan JW, et al
    Evaluating the Population Impact of Intervening on Specific Targets to Reduce HIV Racial/Ethnic Disparities in Adulthood: a Conceptual and Methodological Framework.
    Am J Epidemiol. 2017 Jul 13. doi: 10.1093.
    >> Share

    Antimicrob Agents Chemother

  9. SERRANO-VILLAR S, Caruana G, Zlotnik A, Perez-Molina JA, et al
    The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naive HIV-infected individuals.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01763.
    >> Share

    Antivir Ther

  10. BINDA F, Monge E, Simonetti FR, Zanchetta N, et al
    Primary HIV infection in patients with acute hepatitis B: a report of two cases.
    Antivir Ther. 2017 Oct 12. doi: 10.3851/IMP3201.
    >> Share

  11. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    >> Share

  12. ECKARD AR, O'Riordan MA, Rosebush JC, Lee ST, et al
    Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3199.
    >> Share

  13. JANTARABENJAKUL W, Anugulruengkitt S, Kasipong N, Thammajaruk N, et al
    Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198.
    >> Share

    Clin Infect Dis

  14. KOSS CA, Hosek SG, Bacchetti P, Anderson PL, et al
    Comparison of Measures of Adherence to HIV Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United States.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    >> Share

  15. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
    Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    >> Share

  16. MORIN S, Bazarova N, Jacon P, Vella S, et al
    The manufacturers' perspective on WHO Prequalification of In Vitro Diagnostics.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    >> Share

  17. ABONGOMERA C, Diro E, Vogt F, Tsoumanis A, et al
    The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Clin Infect Dis. 2017 Jul 20. doi: 10.1093.
    >> Share

  18. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
    The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    >> Share

  19. DAVIS AP, Stern J, Tantalo L, Sahi S, et al
    How well do neurologic symptoms identify individuals with neurosyphilis?
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    >> Share

  20. MCCOLLUM ED, Ginsburg AS
    Outpatient Management of Children With World Health Organization Chest Indrawing Pneumonia: Implementation Risks and Proposed Solutions.
    Clin Infect Dis. 2017 Jun 9. doi: 10.1093.
    >> Share

  21. SERPA JA, Rueda AM, Somasunderam A, Utay NS, et al
    Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection.
    Clin Infect Dis. 2017 Jul 7. doi: 10.1093.
    >> Share

  22. DIRO E, Ritmeijer K, Boelaert M, Alves F, et al
    Long-term clinical outcomes in visceral leishmaniasis-HIV co-infected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial Authors and affiliations.
    Clin Infect Dis. 2017 Sep 13. doi: 10.1093.
    >> Share

  23. PARASKEVIS D, Kostaki E, Nikolopoulos GK, Sypsa V, et al
    Molecular tracing of the geographical origin of HIV-1 infection and patterns of epidemic spread among migrants who inject drugs in Athens.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    >> Share

  24. ERLANDSON KM, Kitch D, Wester WC, Kalayjian RC, et al
    The Impact of Statin and ACE-inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with HIV Infection.
    Clin Infect Dis. 2017 Jul 27. doi: 10.1093.
    >> Share

  25. ADU-GYAMFI CG, Snyman T, Hoffmann CJ, Martinson NA, et al
    Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.
    Clin Infect Dis. 2017;65:1356-1358.
    >> Share

  26. COOKSON ST, Maloney SA
    Keeping Up With a World in Motion: Screening Strategies for Migrating Populations.
    Clin Infect Dis. 2017;65:1410-1411.
    >> Share

  27. VAN DUIN D, Bonomo RA
    Reply to Macesic et al.
    Clin Infect Dis. 2017;65:703-704.
    >> Share

  28. ENGELS EA, Yanik EL, Wheeler W, Gill MJ, et al
    Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America.
    Clin Infect Dis. 2017;65:636-643.
    >> Share

  29. SIVRO A, McKinnon LR, Yende-Zuma N, Gengiah S, et al
    Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
    Clin Infect Dis. 2017;65:819-826.
    >> Share

  30. PASTOR L, Casellas A, Ruperez M, Carrillo J, et al
    Interferon-gamma-Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings.
    Clin Infect Dis. 2017 Jul 19. doi: 10.1093.
    >> Share

  31. OLIVER SE, Cope AB, Rinsky JL, Williams C, et al
    Increases in Ocular Syphilis-North Carolina, 2014-2015.
    Clin Infect Dis. 2017 Jul 13. doi: 10.1093.
    >> Share

  32. SALINAS JL, Armstrong LR, Silk BJ, Haddad MB, et al
    Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis - United States, 1993-2013.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    >> Share

  33. BEYENE T, Zewde AG, Balcha A, Hirpo B, et al
    High Dose Fluconazole Monotherapy is Inadequate for CSF Cryptococcal Antigen Positive HIV-infected Persons in an Ethiopian CrAg Screening Program.
    Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
    >> Share

  34. HUGHES AJ, Scheer S
    Evidence of STD testing outside of primary HIV care for people living with HIV in San Francisco, California.
    Clin Infect Dis. 2017 Sep 13. doi: 10.1093.
    >> Share

  35. MARCUS JL, Hurley LB, Nguyen DP, Silverberg MJ, et al
    Redefining HIV Preexposure Prophylaxis Failures.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    >> Share

  36. DESAI SR, Nair A, Rylance J, Mujuru H, et al
    HIV-Associated Chronic Lung Disease in Children and Adolescents in Zimbabwe: Chest Radiographic and High-Resolution Computed Tomography Findings.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    >> Share

  37. HAKRE S, Casimier RO, Danboise BA, Peel SA, et al
    Enhanced Sexually Transmitted Infection Screening for Mycoplasma genitalium in Human Immunodeficiency Virus -Infected US Air Force Personnel.
    Clin Infect Dis. 2017 Aug 9. doi: 10.1093.
    >> Share

  38. JORDAN MR, Penazzato M, Cournil A, Vubil A, et al
    HIV drug resistance in African infants and young children newly diagnosed with HIV: a multicounty analysis.
    Clin Infect Dis. 2017 Aug 8. doi: 10.1093.
    >> Share

  39. LO RE V 3RD
    Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    >> Share

  40. KOUAME GM, Boyd A, Moh R, Badje A, et al
    Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    >> Share

  41. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
    Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    >> Share

  42. PIROTH L, Launay O, Miailhes P, Carrat F, et al
    Isolated anti-HBc serological profile: has the time come to vaccinate?
    Clin Infect Dis. 2017 Sep 15. doi: 10.1093.
    >> Share

  43. VAN DUIN D, Lok JJ, Earley M, Cober E, et al
    Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    >> Share

  44. FLORIDIA M, Ciccacci F, Andreotti M, Hassane A, et al
    Tuberculosis case finding with combined rapid point of care assays (Xpert(R) MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.
    Clin Infect Dis. 2017 Jul 23. doi: 10.1093.
    >> Share

  45. HAVENS PL, Stephensen CB, Van Loan MD, Schuster GU, et al
    Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
    >> Share

  46. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
    Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
    Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
    >> Share

  47. BRUCE RD, Merlin J, Lum PJ, Ahmed E, et al
    2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.
    Clin Infect Dis. 2017 Sep 14. doi: 10.1093.
    >> Share

  48. BALOGUN KA, Lenis MG, Papp E, Loutfy M, et al
    Elevated levels of estradiol in HIV-positive pregnant women on protease inhibitor-based regimens.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    >> Share

  49. WANG H, Wan Z, Xu R, Guan Y, et al
    A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    >> Share

  50. KATZ MJ, Gurses AP, Tamma PD, Cosgrove SE, et al
    Implementing Antimicrobial Stewardship in Long-term Care Settings: An Integrative Review Using a Human Factors Approach.
    Clin Infect Dis. 2017 Jun 20. doi: 10.1093.
    >> Share

  51. PULIDO F, Ribera E, Lagarde M, Perez-Valero I, et al
    Dual therapy with darunavir and ritonavir plus lamivudine versus triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression: randomised, open l
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    >> Share

  52. MODY A, Roy M, Sikombe K, Savory T, et al
    Improved Retention with Six Month Clinic Return Intervals for Stable HIV-Infected Patients in Zambia.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    >> Share

  53. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
    The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    >> Share

    J Acquir Immune Defic Syndr

  54. TANG EC, Vittinghoff E, Anderson PL, Cohen SE, et al
    Changes in Kidney Function Associated with Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001566.
    >> Share

  55. NESHEIM SR, Wiener J, Fitz Harris LF, Lampe MA, et al
    Estimated incidence of perinatally acquired HIV infection in the United States, 1978-2013.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001552.
    >> Share

  56. PRICE JT, Rosenberg NE, Vansia D, Phanga T, et al
    Predictors of HIV, HIV Risk Perception, and HIV Worry among Adolescent Girls and Young Women in Lilongwe, Malawi.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001567.
    >> Share

  57. LALLY MA, van den Berg JJ, Westfall AO, Rudy BJ, et al
    HIV Continuum of Care for Youth in the United States.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001563.
    >> Share

  58. HART BB, Nordell AD, Okulicz JF, Palfreeman A, et al
    Inflammation Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001554.
    >> Share

  59. CARD KG, Armstrong HL, Lachowsky NJ, Cui Z, et al
    Belief in Treatment As Prevention and Its Relationship to HIV Status and Behavioral Risk.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001557.
    >> Share

  60. MUSARANDEGA R, Mutede B, Mahomva A, Nyamayaro W, et al
    Scaling up pediatric HIV testing by incorporating provider-initiated HIV testing into all child health services in Hurungwe District, Zimbabwe.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001564.
    >> Share

  61. CANIGLIA EC, Phillips A, Porter K, Sabin CA, et al
    Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001562.
    >> Share

  62. HAWKINS C, Christian B, Fabian E, Macha I, et al
    Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults.
    J Acquir Immune Defic Syndr. 2017;76:298-302.
    >> Share

  63. LAVERICK R, Haddow L, Daskalopoulou M, Lampe F, et al
    Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV.
    J Acquir Immune Defic Syndr. 2017;76:e74-e83.
    >> Share

  64. PYRA M, Haberer JE, Heffron R, Kidoguchi L, et al
    PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships.
    J Acquir Immune Defic Syndr. 2017 Sep 29. doi: 10.1097/QAI.0000000000001561.
    >> Share

  65. BOCK P, Jennings K, Vermaak R, Cox H, et al
    Incidence of Tuberculosis amongst HIV positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa.
    J Acquir Immune Defic Syndr. 2017 Sep 29. doi: 10.1097/QAI.0000000000001560.
    >> Share

  66. COWGER T, Thai LH, Duong BD, Danyuttapolchai J, et al
    Programmatic Evaluation of an Algorithm for Intensified TB Case Finding and Isoniazid Preventive Therapy for People Living with HIV in Thailand and Vietnam.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001551.
    >> Share

  67. VAN DEN BERG JJ, Javanbakht M, Gorbach PM, Rudy BJ, et al
    Partner Notification for Youth Living with HIV in 14 Cities in the United States.
    J Acquir Immune Defic Syndr. 2017 Oct 4. doi: 10.1097/QAI.0000000000001565.
    >> Share

    J Immunol

  68. MUKHOPADHYAY M, Galperin M, Patgaonkar M, Vasan S, et al
    DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.
    J Immunol. 2017 Oct 9. pii: ji1700953. doi: 10.4049/jimmunol.1700953.
    >> Share

  69. DE GROOT NG, Heijmans CMC, de Ru AH, Janssen GMC, et al
    A Specialist Macaque MHC Class I Molecule with HLA-B*27-like Peptide-Binding Characteristics.
    J Immunol. 2017 Oct 11. pii: ji1700502. doi: 10.4049/jimmunol.1700502.
    >> Share

    J Med Virol

  70. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    >> Share

    J Virol

  71. SHEN X, Basu R, Sawant S, Beaumont D, et al
    HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01077-17. doi: 10.1128/JVI.01077.
    >> Share

  72. PAINTER MM, Zaikos TD, Collins KL
    Quiescence promotes latent HIV infection and resistance to reactivation from latency with histone deacetylase inhibitors.
    J Virol. 2017 Oct 11. pii: JVI.01080-17. doi: 10.1128/JVI.01080.
    >> Share

  73. MCGUIRE EP, Fong Y, Toote C, Cunningham CK, et al
    HIV exposed infants vaccinated with a MF59/rgp120 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01070-17. doi: 10.1128/JVI.01070.
    >> Share

  74. CROMER D, Pinkevych M, Rasmussen TA, Lewin SR, et al
    Modelling of anti-latency treatment in HIV; What is the optimal duration of anti-retroviral-free HIV remission?
    J Virol. 2017 Oct 11. pii: JVI.01395-17. doi: 10.1128/JVI.01395.
    >> Share

    Lancet Gastroenterol Hepatol

  75. MARSHALL AD, Cunningham EB, Nielsen S, Aghemo A, et al
    Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
    Lancet Gastroenterol Hepatol. 2017 Oct 3. pii: S2468-1253(17)30284.
    >> Share

    Lancet HIV

    Working towards HIV prevention choices for women.
    Lancet HIV. 2017 Oct 3. pii: S2352-3018(17)30178.
    >> Share

  77. BEKKER LG, Roux S, Sebastien E, Yola N, et al
    Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Lancet HIV. 2017 Oct 3. pii: S2352-3018(17)30156.
    >> Share

  78. BOYD MA, Cooper DA, Gilks CF
    Towards a universal second-line fixed-dose combination ART.
    Lancet HIV. 2017 Oct 5. pii: S2352-3018(17)30180.
    >> Share

  79. ORKIN C, Molina JM, Negredo E, Arribas JR, et al
    Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically s
    Lancet HIV. 2017 Oct 5. pii: S2352-3018(17)30179.
    >> Share

    MMWR Morb Mortal Wkly Rep

  80. GANT Z, Dailey A, Hu X, Johnson AS, et al
    HIV Care Outcomes Among Hispanics or Latinos with Diagnosed HIV Infection - United States, 2015.
    MMWR Morb Mortal Wkly Rep. 2017;66:1065-1072.
    >> Share

    Nat Rev Immunol

  81. WYKES MN, Lewin SR
    Immune checkpoint blockade in infectious diseases.
    Nat Rev Immunol. 2017 Oct 9. doi: 10.1038/nri.2017.
    >> Share


  82. Increased brain-predicted aging in treated HIV disease.
    Neurology. 2017;89:1652.
    >> Share

    Pediatr Infect Dis J

  83. ROJAS SANCHEZ P, Dominguez S, Jimenez De Ory S, Prieto L, et al
    Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-Infected Pediatric Population in Madrid: 1993-2015 Analysis.
    Pediatr Infect Dis J. 2017 Oct 6. doi: 10.1097/INF.0000000000001760.
    >> Share

  84. STANKIEVICH E, Malanca A, Foradori I, Ivalo S, et al
    Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-Infected Children and Young Adults in Argentina.
    Pediatr Infect Dis J. 2017 Oct 7. doi: 10.1097/INF.0000000000001807.
    >> Share

  85. GIAQUINTO C, Mawela MP, Chokephaibulkit K, Negra MD, et al
    Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
    Pediatr Infect Dis J. 2017 Oct 7. doi: 10.1097/INF.0000000000001808.
    >> Share

    PLoS One

  86. RENIERS G, Blom S, Lieber J, Herbst AJ, et al
    Tuberculosis mortality and the male survival deficit in rural South Africa: An observational community cohort study.
    PLoS One. 2017;12:e0185692.
    >> Share

  87. TIAM A, Gill MM, Hoffman HJ, Isavwa A, et al
    Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks?
    PLoS One. 2017;12:e0184769.
    >> Share

  88. YAP SH, Abdullah NK, McStea M, Takayama K, et al
    HIV/Human herpesvirus co-infections: Impact on tryptophan-kynurenine pathway and immune reconstitution.
    PLoS One. 2017;12:e0186000.
    >> Share

  89. WESTERCAMP N, Mehta SD, Jaoko W, Okeyo TA, et al
    Penile coital injuries in men decline after circumcision: Results from a prospective study of recently circumcised and uncircumcised men in western Kenya.
    PLoS One. 2017;12:e0185917.
    >> Share

  90. MIIRO G, DeCelles J, Rutakumwa R, Nakiyingi-Miiro J, et al
    Soccer-based promotion of voluntary medical male circumcision: A mixed-methods feasibility study with secondary students in Uganda.
    PLoS One. 2017;12:e0185929.
    >> Share

  91. MCCURLEY NP, Domi A, Basu R, Saunders KO, et al
    HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
    PLoS One. 2017;12:e0177863.
    >> Share

  92. LEITMAN EM, Palmer CD, Buus S, Chen F, et al
    Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities.
    PLoS One. 2017;12:e0184496.
    >> Share

  93. MCGRATH CJ, Garcia R, Trinh TT, Richardson BA, et al
    Role of p16 testing in cervical cancer screening among HIV-infected women.
    PLoS One. 2017;12:e0185597.
    >> Share

  94. KIWUWA-MUYINGO S, Nazziwa J, Ssemwanga D, Ilmonen P, et al
    HIV-1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda: A phylogenetic and epidemiological approach.
    PLoS One. 2017;12:e0185818.
    >> Share

  95. BECKMAN JA, Wood BR, Ard KL, Price CN, et al
    Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
    PLoS One. 2017;12:e0181993.
    >> Share

  96. STAVETEIG S, Croft TN, Kampa KT, Head SK, et al
    Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries.
    PLoS One. 2017;12:e0186316.
    >> Share

  97. MONTALTO GJ, Sawe FK, Miruka A, Maswai J, et al
    Diagnosis disclosure to adolescents living with HIV in rural Kenya improves antiretroviral therapy adherence and immunologic outcomes: A retrospective cohort study.
    PLoS One. 2017;12:e0183180.
    >> Share

  98. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    >> Share

    PLoS Pathog

  99. LEIBMAN RS, Richardson MW, Ellebrecht CT, Maldini CR, et al
    Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
    PLoS Pathog. 2017;13:e1006613.
    >> Share


  100. SUN P, Crum-Cianflone NF, Defang G, Williams M, et al
    Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307.
    >> Share


  101. JOSHI A, Cox EK, Sedano MJ, Punke EB, et al
    HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.
    Virology. 2017;512:222-233.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016